This has the potential to be used by the geriatric population in the domestic and point-of-care environment to monitor CTx-I levels in urine on a daily basis in order to avoid musculoskeletal disorders, like bone carcinoma and osteoporosis. This evidence concerns the gene CYP27A1 and osteoporosis.